Risk Factors for Recurrence in Early-Stage Uterine Sarcoma After Surgery

Overview

This study analyzed 55 patients with uterine sarcoma to identify recurrence risk factors following complete surgical resection, focusing on stage I uterine leiomyosarcoma (ULMS) and low-grade endometrial stromal sarcoma (LG-ESS). Findings highlight the high recurrence rate in early-stage ULMS despite complete surgery and underscore the need for tailored postoperative management.

Background

Uterine sarcomas are rare and aggressive malignancies with prognosis varying by histological subtype and stage. Early-stage ULMS has a poor prognosis with high recurrence rates even after complete resection, while LG-ESS generally shows better survival outcomes. Current guidelines do not recommend routine postoperative adjuvant therapy for stage I uterine sarcomas, but some evidence suggests benefits in selected cases. Understanding risk factors for recurrence is critical to guide surgical and adjuvant treatment decisions.

Data Highlights

Key Findings

• Uterine sarcomas represent 4%–9% of uterine malignancies with variable prognosis based on histology and stage.
• Stage I ULMS patients showed a high recurrence rate (13/16) despite complete surgical resection.
• No significant differences in age, delivery history, menopausal status, tumor size, or hematologic findings were found between recurrence and non-recurrence groups in stage I ULMS.
• Current guidelines recommend total hysterectomy and bilateral salpingo-oophorectomy for early-stage uterine sarcomas, but fertility or hormonal preservation may be considered in select cases.
• Postoperative adjuvant therapy is not routinely recommended but may benefit certain histologies such as ULMS and LG-ESS.

Clinical Implications

Clinicians should recognize the high risk of recurrence in early-stage ULMS despite complete surgical resection and consider individualized postoperative management strategies. Decisions regarding fertility or ovarian preservation must balance recurrence risk, especially in estrogen-dependent tumors. Further research is needed to define adjuvant therapy protocols based on identified risk factors to improve outcomes.

Conclusion

This study underscores the importance of identifying recurrence risk factors in early-stage uterine sarcoma to optimize surgical and adjuvant treatment approaches. High recurrence rates in stage I ULMS highlight the need for vigilant postoperative monitoring and potential therapeutic interventions.

References

1. NCCN Guidelines Version 3.2025 -- Uterine Neoplasms
2. Survival rates in uterine sarcoma subtypes -- Various sources
3. Study on postoperative chemotherapy and hormone therapy benefits -- Various sources